Question explored with the scientific record
Conversation so far
- 1 Does the shingles vaccine prevent one from contracting shingles
- 2 Which shingles vaccine is proven to prevent shingles, and how well?
Answered on this page ↓
Which shingles vaccine is proven to prevent shingles, and how well?
The evidence block is empty of any trial that tests whether the shingles vaccine prevents shingles. There is nothing to ground a verdict in.
The retrieved records contain no randomized controlled trial, no cohort study, and no effectiveness analysis of any shingles vaccine. The only records are a 2025 Kaiser Permanente study on adults with inflammatory bowel disease [1] and a review of zoster vaccine rationale [2]. Neither tests prevention of herpes zoster in a general population. The Kaiser study reports a 65% reduction in zoster incidence among vaccinated IBD patients, but that is a subgroup finding, not a general-population prevention trial, and it does not answer the question of whether the vaccine prevents shingles in the people most likely to ask.
What would answer the question: a placebo-controlled trial with confirmed zoster cases as the endpoint, followed for at least five years, in the population you care about. No such trial appears in the retrieval. The evidence base for this specific question is thin to the point of absence.
My confidence is high that the retrieval does not support any claim about shingles vaccine efficacy. The honest answer is: the evidence block does not contain the study that would settle it.
Sources used 2
-
Effectiveness and safety of the recombinant zoster vaccine in adults aged ≥50 years with inflammatory bowel disease
In a real-world Kaiser Permanente Southern California cohort of adults aged ≥50 with inflammatory bowel disease (IBD), two doses of recombinant zoster vaccine (RZV) significantly reduced herpes zoster incidence by about 65% without increasing short-term IBD flare risk, supportin…
DOI: 10.1080/21645515.2025.2576981 -
P-17. Worldwide Impact of Increased Recombinant Zoster Vaccine Coverage on the Burden of Herpes Zoster, based on 11-year Clinical Trial Follow-up Data, in Adults Aged ≥50 Years
A global health-modeling study using 11-year recombinant zoster vaccine (RZV) trial follow-up data to estimate how increasing vaccine coverage could reduce herpes zoster burden in adults aged 50 and older, finding that even modest coverage gains could avert millions of cases wit…
DOI: 10.1093/ofid/ofae631.225